CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong
· Delayed Price · Currency is HKD | Market Cap | 76.49B |
| Revenue (ttm) | 28.94B |
| Net Income (ttm) | 3.71B |
| Shares Out | 11.43B |
| EPS (ttm) | 0.33 |
| PE Ratio | 20.58 |
| Forward PE | 9.61 |
| Dividend | 0.29 (4.36%) |
| Ex-Dividend Date | Jun 24, 2026 |
| Volume | 85,617,749 |
| Average Volume | 98,315,805 |
| Open | 6.67 |
| Previous Close | 6.65 |
| Day's Range | 6.59 - 6.84 |
| 52-Week Range | 6.53 - 11.63 |
| Beta | 0.73 |
| RSI | 32.02 |
| Earnings Date | Aug 21, 2026 |
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]
Financial Performance
In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.
Financial numbers in CNY Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for 1093 stock is "Buy." The 12-month stock price target is $11.57, which is an increase of 72.95% from the latest price.
News
CSPC Pharmaceutical Group Earnings release: Q1 2026
CSPC Pharmaceutical Group released its Q1 2026 earnings on May 27, 2026, summarizing the period's financial results.
CSPC Pharmaceutical Group Slides: Q1 2026
CSPC Pharmaceutical Group has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 27, 2026.
CSPC Pharmaceutical Group Earnings release: Q4 2025
CSPC Pharmaceutical Group released its Q4 2025 earnings on March 25, 2026, summarizing the period's financial results.
CSPC Pharmaceutical Group Slides: Q4 2025
CSPC Pharmaceutical Group has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 25, 2026.
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...
CSPC Pharmaceutical Group Earnings release: Q3 2025
CSPC Pharmaceutical Group released its Q3 2025 earnings on November 19, 2025, summarizing the period's financial results.
CSPC Pharmaceutical Group Slides: Q3 2025
CSPC Pharmaceutical Group has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 19, 2025.
CSPC Pharmaceutical Group Quarterly report: H1 2025
CSPC Pharmaceutical Group has published its H1 2025 quarterly earnings report on August 22, 2025.
CSPC Pharmaceutical Group Earnings release: H1 2025
CSPC Pharmaceutical Group released its H1 2025 earnings on August 22, 2025, summarizing the period's financial results.
CSPC Pharmaceutical Group Slides: H1 2025
CSPC Pharmaceutical Group has posted slides in relation to its H1 2025 quarterly earnings report, which was published on August 22, 2025.